nMFI-based CD38 expression levels in diagnostic, MRD, refractory and relapsed samples
| Diagnostic | MRD | Refractory disease | Relapse | |
| CD38+ | 184/188 (97.9%) | 87/100 (79.1%) | 23/24 (95.8%) | 29/35 (82.86%) |
| Dim to negative | 81/184 (44.01%) | 27/87 (31.03%) | 7/23 (30.43%) | 05/29 (17.24%) |
| Dim | 40/184 (21.74%) | 17/87 (19.54%) | 5/23 (21.74%) | 07/29 (24.14%) |
| Moderate | 51/184 (27.72%) | 27/87 (31.03%) | 8/23 (34.78%) | 12/29 (41.38%) |
| Bright | 12/184 (06.52%) | 16/87 (18.4%) | 3/23 (13.04%) | 05/29 (17.24%) |
MFI, mean fluorescence intensity; MRD, measurable residual disease; nMFI, normalized MFI.